REBORNE

Dr Pierre Layrolle

Scientific Coordinator of REBORNE, based at Institut National de la Santé et de la Recherche Médicale (Inserm) in Nantes, France

Research field

Regenerative Medicine, Stem Cells, Biomaterials

If you like this

If you want to know more

Who?

“How to mimic the complexity of living tissues, particularly bone, is my search for the Grail!”, says Pierre Layrolle, Director of Research at Inserm in France. “Our method is unique: we use mesenchymal stem cells. These are connective tissue cells that can differentiate into various cell types such as bone or cartilage.”

Why?

Bone is the most frequently transplanted human tissue: around one million bone transplantations are performed annually in Europe. Bone grafts from the patient or a donor are primarily used for these surgical procedures. However, these methods have drawbacks and complications are often observed after surgery.

What?

REBORNE aims to develop a new method to heal bone fractures. Dr Layrolle: “We combine mesenchymal stem cells and biomaterials to regenerate bone tissue. The stem cells are extracted from bone marrow, amplified in the laboratory, associated with a synthetic biomaterial, and then transplanted into the fracture”.

How?

The REBORNE project involves 24 participants from eight European countries. This consortium of world-class laboratories, cell production units, small enterprises and hospitals will collaborate to reach the ambitious goal of REBORNE: completing five multicentre clinical trials using advanced biomaterials and stem cells.

Towards bone regeneration without complications

Result of an experiment: bone (green) and bone marrow (red) are formed after implantation of a mixture of human stem cells and biomaterial granules (grey/white) beneath the skin in a laboratory mouse

Reborne principle

Image credit: P.Layrolle, Inserm

The REBORNE project involves 24 partners from eight European countries

Bone tissue engineering

‹ ›

REBORNE project website Institut National de la Santé et de la Recherche Médicale (Inserm) European Society of Gene and Cell Therapy (ESGCT) International Society for Cellular Therapy (ISCT) committee for Advanced Therapies (CAT) - European Medicines Agency (EMEA)

PDF version

Background image: REBORNE

Portrait of the project coordinator: REBORNE

Timeline (in chronological order): 1908: CTT Journal Vol. 1 No. 3 2009 Creative Commons Attribution; 1968: Navy News Service, 021204-N-0696M-180; 2008: kennislink.nl